Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal
- Written by PR Newswire
 |
Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder
SYDNEY, Feb. 12, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the publication of its most recent peer-reviewed journal article entitled Clinical Pharmacology...
